Treatment of Diffuse Anterior Scleritis
For diffuse anterior scleritis with low-grade inflammation (≤2+) and no ocular complications, start with oral NSAIDs; if inflammation is severe (>2+), initiate oral corticosteroids; for cases with associated systemic disease or those failing NSAIDs/steroids, escalate to immunosuppressive therapy. 1
Initial Treatment Algorithm
Step 1: Assess Disease Severity and Systemic Association
Before selecting therapy, determine:
- Degree of scleral inflammation (grade 0 to 4+)
- Presence of ocular complications (anterior uveitis, keratitis, elevated IOP)
- Associated systemic disease (rheumatoid arthritis, granulomatosis with polyangiitis, inflammatory bowel disease)
- Bilateral vs unilateral involvement
Step 2: First-Line Therapy Selection
For idiopathic diffuse scleritis with mild-moderate inflammation (≤2+):
- Start oral NSAIDs as first-line therapy 1, 2
- Celecoxib 200-400 mg daily (divided doses) is particularly effective with fewer GI side effects 3
- Alternative NSAIDs: indomethacin 75-150 mg daily or naproxen 500-1000 mg daily
- Expect clinical response within 5-7 days 3
- Success rate: 93% in idiopathic cases without complications 1
For idiopathic diffuse scleritis with severe inflammation (>2+):
- Start oral corticosteroids (prednisone 1 mg/kg/day, maximum 60-80 mg) 1, 2
- Taper gradually once inflammation controlled (typically over 6-8 weeks)
- Maintain NSAIDs during steroid taper when possible
- Success rate: 84% as initial therapy 2
Step 3: Second-Line Therapy (Treatment Failure at 2-4 Weeks)
If NSAIDs fail (7-9% failure rate in diffuse scleritis 2):
- Add or switch to oral corticosteroids 1, 2
- Continue NSAIDs if partial response achieved
- Taper steroids as soon as inflammation controlled while maintaining NSAIDs
If corticosteroids fail or cannot be tapered (16-28% failure rate 2):
- Escalate to immunosuppressive therapy (see Step 4)
Step 4: Immunosuppressive Therapy
Indications for immunosuppression:
- Diffuse scleritis with associated systemic disease 1
- Steroid-dependent disease (cannot taper below 10 mg prednisone daily)
- Recurrent disease despite NSAIDs/steroids
- Bilateral disease with systemic involvement
First-line immunosuppressive agents:
- Methotrexate 15-25 mg weekly (oral or subcutaneous) with folic acid supplementation
- Mycophenolate mofetil 1000-1500 mg twice daily
- Success rate with immunosuppression: 73-75% 1, 2
For refractory cases or rapidly progressive disease:
- Biologic therapy (anti-TNF agents preferred) 1
- Adalimumab 40 mg subcutaneously every 2 weeks
- Infliximab 3-5 mg/kg IV at weeks 0,2,6, then every 4-8 weeks
- Success rate with biologics: associated with systemic disease cases (OR 3.15) 1
Local Therapy Considerations
Subconjunctival/sub-Tenon triamcinolone injections:
- Consider for steroid-dependent cases or as steroid-sparing adjunct 4, 5
- Dose: 2-4 mg preservative-free triamcinolone at site of inflammation 5
- Provides 4-5 months symptom-free interval on average 5
- Monitor closely for: IOP elevation (occurs in ~17% of cases) and cataract progression 5
- Allows reduction or discontinuation of systemic therapy 4, 5
Important caveat: Topical corticosteroids and NSAIDs have minimal efficacy in scleritis (unlike episcleritis) and should not be used as monotherapy 6.
Monitoring and Follow-Up
- Initial phase: Weekly assessment until inflammation controlled
- Maintenance phase: Every 2-4 weeks during medication taper
- Monitor for complications: Anterior uveitis, keratitis, elevated IOP, scleral thinning (especially in recurrent cases—occurs in 42% 7)
- Anterior segment OCT can quantify scleral thickness changes (mean thickness 922 μm in active disease vs 798 μm in controls) 7
Critical Pitfalls to Avoid
- Do not use topical therapy alone—scleritis requires systemic treatment in most cases
- Do not delay immunosuppression in patients with associated systemic disease (especially potentially lethal conditions like granulomatosis with polyangiitis)
- Do not abruptly stop corticosteroids—taper gradually while maintaining NSAIDs or adding immunosuppression
- Do not miss systemic workup—complete rheumatologic evaluation essential, as 39-57% have associated systemic disease 1
- Monitor for steroid complications when using local injections—IOP checks mandatory 5